Highest-materiality recent filing
Scilex extends $20M uncommitted revolving credit line to Vivasor at 5% interest
Effective Aug 8, 2026, Scilex provided Vivasor, Inc. an uncommitted revolving credit line up to $20M.
Scilex sells Vivasor preferred shares for $12M; CEO Henry Ji on both sides
Scilex sells 6.1M Series A-1 and 355.9K Series A-2 Vivasor preferred shares for $12M ($1.8583/share).
Scilex signs binding term sheet for $100M investment from iHolding at $15/share
iHolding to purchase $100M of newly issued shares at $15/share (~6.67M shares).
Scilex signs binding term sheet to buy 837 Bitcoin from Datavault for $50M
Purchase of 837 BTC from Datavault AI Inc. for $50M; initial $30M cash payment due at closing.
Scilex stockholders elect director, ratify auditor, approve equity plan share increase
Dorman Followwill elected Class I director: 3,945,473 for, 410,969 withhold, 1,880,745 broker non-votes.
Scilex declares dividend of Dream Bowl Meme Coin I tokens; 5 tokens per share; payment begins May 26
Record date Apr 30, 2026; holders of common, certain warrants, convertible notes, Series A preferred eligible.
Scilex subsidiary to sell ACEA Pharma to Phoenix Asia for $1B in stock, owning 82% post-close
ACEA Thera sells 100% of ACEA Pharma to Phoenix Asia for 100M shares at $10/share, valued at $1B.
Scilex to pay $120M to Datavault for quantum GPU network, revenue-sharing deal
Upfront cash contribution of $120M to Datavault, payable in multiple closings by Dec 31, 2026.
Complaint filed March 11, 2026, against Marc Wade, St. James Bank, Omega & Corinth, and BNY Mellon.
Scilex files federal securities fraud lawsuit over 96M misappropriated Datavault collateral shares
Filed complaint in Central District of California against Marc Wade, St. James Bank, Omega & Corinth, and BNY Mellon.
Scilex issues warrant to Oramed for 100,000 shares at $20.00 in exchange for payment deferral
Warrant for 100,000 shares at $20.00 issued to Oramed Pharmaceuticals for deferring an amortization payment originally due Oct 1, 2025.
Scilex board revokes declared preferred stock dividend; no shares ever issued
Board revoked stock dividend of 5M Series 1 Mandatory Exchangeable Preferred shares on Feb 2, 2026.
Scilex loans $20M to Q Scan, converts to shares; agrees $27.5M stock purchase
Loaned $20M to Q Scan via convertible note; note converted same day into 140.4M Q Scan common shares.
Completed second tranche of warrant repurchase on Dec 30, 2025 for $14M, following $13M first tranche in Sep 2025.
Scilex closes $22.6M first tranche of previously announced $50M non-recourse loan
First tranche of $50M loan from The St. James Bank & Trust Company Ltd. closed on Dec 22, 2025.
Scilex subsidiary enters $100M non-recourse loan secured by SCLX pledge
Up to $100M in tranches at lender's sole discretion; interest at 12-month SOFR.
Scilex amends loan: principal up to $100M, collateral 85.8M Datavault shares
Loan facility increased from $50M to $100M under amendment dated Dec 8, 2025.
Scilex stockholders approve repricing of stock options from $282.80 to $16.80 per share
Stockholders approved repricing of up to 289,405 options held by employees, executives, and board members.
Scilex secures up to $50M non-recourse loan secured by 39.2M shares of Datavault AI (DVLT)
Loan of up to $50M in tranches at 12-month SOFR + 2.0% interest, maturity 4 years from first tranche.
Scilex completes $150M Bitcoin investment in Datavault AI, warrant shares now valued at $583M
Scilex purchased a pre-funded warrant for 263,914,094 Datavault shares in the second tranche, paying in Bitcoin.
Scilex receives $20.4M from Armistice warrant exercise; issues new warrants for 1.36M shares
Existing warrants (904,396 shares) exercised at reduced price $22.51/share, gross proceeds $20.36M.
Scilex in-licenses Datavault AI tech for biotech asset tokenization; $10M upfront, $2.55B milestones
Worldwide exclusive license from Datavault AI for tokenizing genomic, DNA, diagnostic, therapeutic data in biotech/pharma.
Scilex terminates ELOC with Tumim; to pay $2.7M cash instead of issuing 150k shares
Scilex and Tumim Stone Capital terminated their July 22, 2025 ELOC agreement.
Scilex appoints Stephen Ma as COO; he continues as CFO
Stephen Ma, 53, appointed COO effective Oct 1, 2025; retains CFO, SVP, Corporate Secretary, and Board roles.
Scilex enters warrant exercise agreement for $2.7M proceeds; issues new warrants for 275K shares
Existing warrant holders exercise 179,236 shares at net $15.00/share after $7.72 deferral fee, raising ~$2.7M.
Scilex directors Navani and Shah resign; CFO Ma joins board; consulting pact with Shah affiliate
Annu Navani and Jaisim Shah resigned as directors on Sept 22, 2025, in connection with the Semnur business combination.
Scilex sells 12.5M Semnur shares for $200M Bitcoin; closes Sept 23, 2025
Scilex sold 12,500,000 Semnur common shares at $16.00/share to Biconomy for $200M in Bitcoin.
Scilex invested $150M in Bitcoin for Datavault AI (DVLT) shares and warrants at $0.5378 per share effective price.
Scilex CEO Jaisim Shah resigns to focus on Semnur; Henry Ji appointed CEO; Semnur gets $20M PIPE
Jaisim Shah resigned as CEO/President of Scilex effective Aug 17, 2025; remains on Board and will focus full time on Semnur.
Scilex enters $100M equity line, exchanges warrants, gets option to repurchase Penny Warrants
Equity line with Tumim Stone Capital: up to $100M common stock at 96-97% of lowest VWAP; 150k commitment shares.
Scilex subsidiary Semnur amends Denali merger deal to allow additional share issuances pre-closing
Amendment modifies Exchange Ratio and Merger Consideration definitions to account for shares issued after signing date (PIPE/Advisor Shares).
Scilex stockholder meeting elects Shah and Ji as directors, ratifies BPM auditor
Jaisim Shah elected with 3,537,589 votes for; Henry Ji with 3,433,624 votes for.
Scilex defers record date for preferred stock dividend to future date determined by Board
Record date shifted from May 2, 2025 to a later date to be set by the Board.
Scilex annual meeting adjourned due to lack of quorum; reconvenes June 20
Annual meeting convened and adjourned on June 4, 2025, without conducting business due to insufficient quorum.
Scilex adjusts non-employee director equity grants post 1-for-35 reverse stock split
Initial option grant reduced from 250,000 to 7,142 shares per new director.
Scilex regains Nasdaq minimum bid price compliance as of April 30, 2025
Nasdaq notified Scilex on April 30, 2025 that compliance with Rule 5550(a)(2) was regained.
Dividend of Series 1 Mandatory Exchangeable Preferred Stock (exchangeable for up to 10% of Semnur Pharmaceuticals stake) record date moved from April 11 to May 2, 2025.
Amendment dated April 16, 2025 modifies covenants to address Denali's de-listing from Nasdaq and subsequent quotation on OTC Markets.
Board set ratio at 1-for-35 on April 3, 2025; stockholders approved March 19, 2025.
Scilex announces 1-for-35 reverse stock split effective April 15, 2025 to regain Nasdaq compliance
Ratio of 1-for-35; effective 12:01 a.m. ET on April 15, 2025.
Scilex shareholders approve reverse stock split within 1:14 to 1:50 range
Shareholders approved reverse stock split of common stock at ratio between 1:14 and 1:50; board to set final ratio by March 19, 2026.
Scilex changes record date for preferred stock dividend from Jan 28 to Apr 11, 2025
New record date for Dividend of Series 1 Mandatory Exchangeable Preferred Stock is April 11, 2025 (previously Jan 28).
Scilex sells 4% royalty on Gloperba/Elyxyb to defer Tranche B amortization to 2026
Sold 4% of aggregate net sales of Gloperba and Elyxyb to Oramed, Murchinson, and 3i; consideration is deferral of First Amortization Payment on Tranche B Notes to Oct 8, 2026.
Scilex voluntarily terminates ATM equity offering agreement with sales agents
Sales Agreement with B. Riley, Cantor Fitzgerald, and H.C. Wainwright terminated effective March 5, 2025; no penalty incurred.
Scilex licenses ZTlido and SP-103 to RoyaltyVest for ex-US markets; 50% net revenue share
Licensed ZTlido (lidocaine topical system 1.8%) and SP-103 for commercialization outside US; Licensor retains US and stated territories.
Scilex extends Oramed note maturity to Dec 2025; issues 3.25M shares as consideration
Maturity date of Oramed Senior Secured Promissory Note extended from March 21, 2025 to December 31, 2025.
Scilex regains Nasdaq compliance by filing overdue Q3 2024 10-Q
Filed Form 10-Q for quarter ended Sept 30, 2024 on Jan 17, 2025, curing late filing.
Scilex defers $6.25M amortization payment, issues 5M shares to noteholders
Entered deferral letters with Tranche B noteholders; first $6.25M amortization due Jan 2 deferred to Jan 31, then to Oct 8, 2026.
Scilex moves preferred stock dividend record date to Jan 28, 2025; payment by Mar 29
Record date changed from Nov 7, 2024 to Jan 28, 2025 for Series 1 Mandatory Exchangeable Preferred Stock dividend.
Scilex raises $17M in registered direct offering, plus $1M warrant exercise
Gross proceeds ~$17M from sale of 26.355M shares, pre-funded warrants, and 57.513M common warrants.
On November 27, 2024, David Lemus notified the Board of Directors (the “ Board ”) of Scilex Holding Company (the “ Company ”) that he was resigning from the Board, all committees of the Board and any director or officer position held with any subsidiary of the Company, effective as of November 27, 2024, for personal and professional reasons.
On July 21, 2024, Scilex Holding Company (the “ Company ”) appointed Annu Navani, M.D. as a Class II director of the Company and as a member of the Commercialization and Transaction Committee of the Board of Directors of the Company (the “ Board ”).
On September 21, 2023, Laura J. Hamill notified the Board of Directors (the “ Board ”) of the Company that she was resigning from the Board, all committees of the Board and any director or officer position held with any subsidiary of the Company, effective as of September 21, 2023.
On September 20, 2023, Elizabeth Czerepak, the Executive Vice President, Chief Business Officer, Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer and Secretary of Scilex Holding Company (the “ Company ”), resigned from the Company, effective immediately.
On September 22, 2023, the Company appointed Stephen Ma, age 51, as the Company’s Chief Financial Officer, effective immediately.
On August 27, 2023, Tien-Li Lee, M.D. notified the Board of Directors (the “Board”) of the Company that he was resigning from the Board, all committees of the Board and any director or officer position held with any subsidiary of the Company, effective as of August 27, 2023.
On August 28, 2023, each of Dorman Followwill and David Lemus notified the Board that he was resigning from the Board, all committees of the Board and any director or officer position held with any subsidiary of the Company, effective as of and contingent upon the closing of the Oramed Transaction.
On August 28, 2023, each of Dorman Followwill and David Lemus notified the Board that he was resigning from the Board, all committees of the Board and any director or officer position held with any subsidiary of the Company, effective as of and contingent upon the closing of the Oramed Transaction.
On August 27, 2023, Dr. Ji notified the Board that he was resigning from his position as an executive officer of the Company and any position as a director or officer of any subsidiary of the Company, effective as of and contingent upon the closing of the Oramed Transaction.
On August 27, 2023, Henry Ji, Ph.D. was informed that, pursuant to Article V.E. of the Company’s Restated Certificate of Incorporation, the chief restructuring officer on behalf of Sorrento in its pending bankruptcy proceedings, as the holder of a majority in voting power of the then-outstanding shares of stock of the Company entitled to vote generally in the election of directors, had taken action by written consent to remove Dr. Ji as a director of the Company, effective as of such date.
On August 27, 2023, Laura J. Hamill notified the Board that she was resigning from the Board, all committees of the Board and any director or officer position held with any subsidiary of the Company effective as of and contingent upon the closing of the Oramed Transaction.
On August 29, 2023, Jaisim Shah notified the Board that he was retiring from the Board, all committees of the Board, his position as the Chief Executive Officer and President of the Company and any position as a director or officer of any subsidiary of the Company, effective as of and contingent upon the closing of the Oramed Transaction.
Max materiality 0.85 · Median 0.60 · Most common event other_material